Clinical Trial Update: Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating cetuximab added to concurrent chemoradiotherapy platforms for locally advanced head and neck cancer; results completed and poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: University of Chicago | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-10-09